NEW YORK, April 18 - Qiagen said today it has bought Xeragon for about $8 million as part of its goal of expanding its oligonucleotide business.
Qiagen paid for the deal by issuing 564,000 shares in exchange for all of the outstanding capital stock of Xeragon. Qiagen said it may issue an additional payment of up to $1.2 million in cash or stock if certain performance targets are met by next December.
Xeragon's 2003 product line is expected to contribute $4 million in net sales and $1 million in net income to Qiagen, the Dutch genomics firm said.
Xeragon, based in Huntsville, Ala., has a staff of 10.